FDA greenlights first vaccine for RSV prevention in infants via active gestational immunization

The Food and Drug Administration announced its approval of Pfizer’s Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease and severe LRTD caused by respiratory syncytial virus in infants from birth through six months of age. FDA says Abrysvo is approved for use at 32 through 36 weeks gestational age of pregnancy. The approval follows a clinical study that confirmed Abrysvo’s effectiveness to prevent LRTD and severe LRTD caused by RSV in infants born to individuals who were vaccinated during pregnancy.
Related News Articles
Headline
Nearly 57% of mothers did not attend a postpartum follow-up visit three to eight weeks after giving birth, according to a report published July 29 by Cedar…
Headline
The Senate Appropriations Committee July 31 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services,…
Headline
The Joint Commission July 29 announced an initiative to address “gaps” in how children’s hospitals are accredited and certified. The program will remove or…
Headline
Five pediatric flu deaths were reported to the Centers for Disease Control and Prevention last week, pushing the total to 266 for the 2024-2025 flu season,…
Headline
The AHA July 24 announced it is collaborating with health care technology leader Epic to help hospitals adopt tools that support the early detection and…
Headline
The Department of Health and Human Services July 23 announced it is recommending the removal of thimerosal from all U.S. flu vaccines. The announcement follows…